Study of XL999 in Patients With Previously Treated Ovarian Cancer
Status:
Terminated
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This clinical trial is being conducted at multiple sites to evaluate the activity, safety,
and tolerability of XL999 when given weekly to patients with ovarian cancer that has
previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor
of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor
cell growth, formation of new blood vessels (angiogenesis), and metastasis.